ANZGOG’s gynaecological cancer clinical trials are conducted cooperatively by multidisciplinary teams of researchers.

More than 50 hospitals in Australia and New Zealand are recruiting participants to ANZGOG clinical trials in ovarian, endometrial, and cervical cancer.

Many of our trials are developed and led by ANZGOG members, others are part of an international collaboration where ANZGOG leads the Australian and New Zealand operations. In this way we are able to offer a wide range of trials and fast-track new treatments for women in Australia and New Zealand.

All clinical trials recruiting patients in Australia and New Zealand can be found on the Australia New Zealand Clinical Trials Registry

Gynaecological cancer clinical trials currently recruiting

OVARIAN

iPRIME
ACTRN12618000109202

A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”.

Trial details

OVARIAN

EMBRACE
ACTRN12617000855325

A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2).

Trial details

OVARIAN

ECHO
ACTRN12614001311640 

A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first-line treatment for ovarian cancer.

Trial details

OVARIAN

 ICON9

ACTRN12618000498291

 

 

A Phase III randomised study to evaluate the efficacy of maintenance therapy with olapraib and cediranib or olaparib alone in patients with relapsed ovarian cancer following a response to platinum-based chemotherapy

Trial details

OVARIAN

VIP

NCT03188159

Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer

Trial details

OVARIAN

NEO

Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer.

The NEO study has been funded through ANZGOG’s Fund for New Research. It is led by Auckland District Hospital Board New Zealand.

More information

OVARIAN

SOLACE2 

ACTRN12618000686202

 

A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.

Trial details

ENDOMETRIAL

feMMe
NCT01686126

A Phase II Randomised Clinical Trial of Mirena® ± Weight Loss Intervention in Patients with Early Stage Cancer of the Endometrium.

Trial details

CERVICAL

EXCISE
ACTRN12617000132347

Excisional treatment in women with cervical adenocarcinoma-in-situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure to cold knife cone biopsy.

The pilot of the EXCISE trial has been funded through ANZGOG’s Fund for New Research. It is led by the St John of God Subiaco Hospital.

Trial details